Perioperative toripalimab regimen extends EFS in resectable stage III NSCLC

A combination of toripalimab and perioperative chemotherapy significantly extended EFS compared with chemotherapy alone among patients with resectable stage III non-small cell lung cancer, according to results of a randomized phase 3 study.The findings of the Neotorch study, presented during an ASCO Plenary Series session, also showed the addition of toripalimab (Junshi Biosciences) to

Related Keywords

China ,Texas ,United States ,Suzhou ,Jiangsu ,Yuhan ,Anhui ,Shanghai ,Hutchison Medipharma ,Tina Cascone ,Mindy Valcarcel ,Hansoh Pharma ,Junshi Biosceinces ,Bydevin Mclaughlin ,Junshi Biosciences ,P Tina Cascone ,Serono ,Pfizer ,Shanghai Lung Cancer Center ,Simcere Pharmaceutical Group ,Boehringer Ingelheim ,Bristol Myers Squibb ,Genentech ,Astrazeneca ,Zai Lab ,University Of Texas Md Anderson Cancer Center ,Hengrui Therapeutics ,Lilly Suzhou Pharmaceutical ,Prime Oncology ,Shanghai Chest Hospital ,Shanghai Jiao Tong University ,Cancer Center ,